Web: Novartis external link
Ort: Basel
Kategorie: Medizin/Pharmakologie
Verwandt mit:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Betriebswissenschaft 25.10
Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters Q3 net sales (-1% cc and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301 million)
Medizin 18.10

Alcon to host first live training program on the use of the CyPass Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle gla

Medizin 8.10

Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care LEE01

Medizin 3.10

Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment * -   Majority (84%) face discrimination

Medizin 9.10

Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in ALKi-n

Medizin 8.10

Novartis' Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up Latest data confirm an estimated 45% of p

Medizin 1.10

Cosentyx delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years New data show that wit


Medicine and Life Sciences